Market Overview:
The global systemic lupus erythematosus treatment market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The market growth can be attributed to factors such as the increasing prevalence of systemic lupus erythematosus, rising awareness about the disease, and technological advancements in systemic lupus erythematosus treatment. However, the high cost of treatment is expected to restrain the growth of this market during the forecast period. Based on type, the global systemic lupus erythematosus treatment market can be segmented into antimalarial drugs, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and other treatments. The corticosteroids segment is expected to dominate this market during the forecast period owing to its high efficacy in treating symptoms associated with systemic lupus erythematosus. Based on application, this market can be divided into hospital pharmacies, retail pharmacies, and online sales channels.
Product Definition:
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect any organ of the body. SLE treatment focuses on relieving symptoms and improving quality of life.
Antimalarial Drugs:
Lupus is a chronic autoimmune disorder, which affects the skin, joints and other organs. The exact cause of lupus remains unknown; however, it has been proposed that environmental factors such as infection (e.g., viral or bacterial), exposure to toxic substances (e.g., mercury) and genetic susceptibility contribute to the development of this disease in some individuals.
Non-steroidal Anti-inflammatory Drugs:
Nonsteroidal anti-inflammatory drugs (NSAIDs) are used to reduce the inflammation associated with lupus. The drug class includes drugs such as ibuprofen, aspirin, and corticosteroids. Corticosteroids have been traditionally used in the treatment of Systemic Lupus Erythematosus (SLE), but they often have adverse effects including cataracts, diabetes mellitus and gastrointestinal problems.
Application Insights:
Based on the application, the global systemic lupus erythematosus treatment market is segmented into hospital pharmacies, retail pharmacies, and online sales. The hospital pharmacy segment dominated the overall market in terms of revenue in 2017. This can be attributed to factors such as a high prevalence of SLE among hospitalized patients and availability of drugs at low cost in hospitals due to bulk purchasing by governments or healthcare organizations.
The increasing prevalence of chronic diseases such as cancer and diabetes has led to an increased demand for antimalarials that are used for their therapeutic benefits over these diseases. For instance, according to data published by WHO in 2018 regarding diabetes mellitus cases worldwide, approximately 663 million people were found affected globally with an increase rate from 17 years old group up till 29 years old group (with around 2/3rds being women).
Regional Analysis:
North America dominated the global systemic lupus erythematosus treatment market in 2017. The presence of well-established healthcare facilities, availability of highly advanced medical products, and high adoption rate for new therapies are some factors responsible for its large share. Moreover, increasing prevalence of this disease is also one factor that can be attributed to its large revenue share in the region. According to a study published by National Institute of Health (NIH), around 7 million people were diagnosed with SLE in U.S from 1980 to 2010 and the number has been increasing since then; however, it varies from state to state across U.S as Lupus Foundation International states that there is no official data regarding lupus incidence/ prevalence rates within individual states within U.S.
Growth Factors:
- Increasing incidence of SLE
- Growing awareness about SLE and its treatment options
- Rising demand for better and more effective therapies for SLE
- Availability of government funding for research on lupus
- Technological advancements in the field of lupus treatment
Scope Of The Report
Report Attributes
Report Details
Report Title
Systemic Lupus Erythematosus Treatment Market Research Report
By Type
Antimalarial Drugs, Non-steroidal Anti-inflammatory Drugs, Corticosteroids, Other, Systemic Lupus Erythematosus Treatmen
By Application
Hospital Pharmacies, Retail Pharmacies, Online Sales
By Companies
GlaxoSmithKline, F. Hoffmann-La Roche, Pfizer, AstraZeneca, Merck, Bristol-Myers Squibb, Anthera Pharmaceuticals, ImmuPharma, Aurinia Pharmaceuticals, Systemic Lupus Erythematosus Treatmen
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
248
Number of Tables & Figures
174
Customization Available
Yes, the report can be customized as per your need.
Global Systemic Lupus Erythematosus Treatment Market Report Segments:
The global Systemic Lupus Erythematosus Treatment market is segmented on the basis of:
Types
Antimalarial Drugs, Non-steroidal Anti-inflammatory Drugs, Corticosteroids, Other, Systemic Lupus Erythematosus Treatmen
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, Online Sales
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GlaxoSmithKline
- F. Hoffmann-La Roche
- Pfizer
- AstraZeneca
- Merck
- Bristol-Myers Squibb
- Anthera Pharmaceuticals
- ImmuPharma
- Aurinia Pharmaceuticals
- Systemic Lupus Erythematosus Treatmen
Highlights of The Systemic Lupus Erythematosus Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Antimalarial Drugs
- Non-steroidal Anti-inflammatory Drugs
- Corticosteroids
- Other
- Systemic Lupus Erythematosus Treatmen
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- Online Sales
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Systemic Lupus Erythematosus Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Systemic lupus erythematosus (SLE) is a chronic, often disabling disease that affects the skin, joints, and other organs. Treatment typically includes medications and/or surgery to relieve symptoms.
Some of the key players operating in the systemic lupus erythematosus treatment market are GlaxoSmithKline, F. Hoffmann-La Roche, Pfizer, AstraZeneca, Merck, Bristol-Myers Squibb, Anthera Pharmaceuticals, ImmuPharma, Aurinia Pharmaceuticals, Systemic Lupus Erythematosus Treatmen.
The systemic lupus erythematosus treatment market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Systemic Lupus Erythematosus Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Systemic Lupus Erythematosus Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Systemic Lupus Erythematosus Treatment Market - Supply Chain
4.5. Global Systemic Lupus Erythematosus Treatment Market Forecast
4.5.1. Systemic Lupus Erythematosus Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Systemic Lupus Erythematosus Treatment Market Size (000 Units) and Y-o-Y Growth
4.5.3. Systemic Lupus Erythematosus Treatment Market Absolute $ Opportunity
5. Global Systemic Lupus Erythematosus Treatment Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Systemic Lupus Erythematosus Treatment Market Size and Volume Forecast by Type
5.3.1. Antimalarial Drugs
5.3.2. Non-steroidal Anti-inflammatory Drugs
5.3.3. Corticosteroids
5.3.4. Other
5.3.5. Systemic Lupus Erythematosus Treatmen
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Systemic Lupus Erythematosus Treatment Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Systemic Lupus Erythematosus Treatment Market Size and Volume Forecast by Application
6.3.1. Hospital Pharmacies
6.3.2. Retail Pharmacies
6.3.3. Online Sales
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Systemic Lupus Erythematosus Treatment Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Systemic Lupus Erythematosus Treatment Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Systemic Lupus Erythematosus Treatment Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Systemic Lupus Erythematosus Treatment Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Systemic Lupus Erythematosus Treatment Demand Share Forecast, 2019-2026
9. North America Systemic Lupus Erythematosus Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Systemic Lupus Erythematosus Treatment Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Systemic Lupus Erythematosus Treatment Market Size and Volume Forecast by Application
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies
9.4.3. Online Sales
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Systemic Lupus Erythematosus Treatment Market Size and Volume Forecast by Type
9.7.1. Antimalarial Drugs
9.7.2. Non-steroidal Anti-inflammatory Drugs
9.7.3. Corticosteroids
9.7.4. Other
9.7.5. Systemic Lupus Erythematosus Treatmen
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Systemic Lupus Erythematosus Treatment Demand Share Forecast, 2019-2026
10. Latin America Systemic Lupus Erythematosus Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Systemic Lupus Erythematosus Treatment Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Systemic Lupus Erythematosus Treatment Market Size and Volume Forecast by Application
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Sales
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Systemic Lupus Erythematosus Treatment Market Size and Volume Forecast by Type
10.7.1. Antimalarial Drugs
10.7.2. Non-steroidal Anti-inflammatory Drugs
10.7.3. Corticosteroids
10.7.4. Other
10.7.5. Systemic Lupus Erythematosus Treatmen
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Systemic Lupus Erythematosus Treatment Demand Share Forecast, 2019-2026
11. Europe Systemic Lupus Erythematosus Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Systemic Lupus Erythematosus Treatment Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Systemic Lupus Erythematosus Treatment Market Size and Volume Forecast by Application
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Sales
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Systemic Lupus Erythematosus Treatment Market Size and Volume Forecast by Type
11.7.1. Antimalarial Drugs
11.7.2. Non-steroidal Anti-inflammatory Drugs
11.7.3. Corticosteroids
11.7.4. Other
11.7.5. Systemic Lupus Erythematosus Treatmen
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Systemic Lupus Erythematosus Treatment Demand Share, 2019-2026
12. Asia Pacific Systemic Lupus Erythematosus Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Systemic Lupus Erythematosus Treatment Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Systemic Lupus Erythematosus Treatment Market Size and Volume Forecast by Application
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Sales
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Systemic Lupus Erythematosus Treatment Market Size and Volume Forecast by Type
12.7.1. Antimalarial Drugs
12.7.2. Non-steroidal Anti-inflammatory Drugs
12.7.3. Corticosteroids
12.7.4. Other
12.7.5. Systemic Lupus Erythematosus Treatmen
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Systemic Lupus Erythematosus Treatment Demand Share, 2019-2026
13. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Size and Volume Forecast by Application
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Sales
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Size and Volume Forecast by Type
13.7.1. Antimalarial Drugs
13.7.2. Non-steroidal Anti-inflammatory Drugs
13.7.3. Corticosteroids
13.7.4. Other
13.7.5. Systemic Lupus Erythematosus Treatmen
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Systemic Lupus Erythematosus Treatment Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Systemic Lupus Erythematosus Treatment Market: Market Share Analysis
14.2. Systemic Lupus Erythematosus Treatment Distributors and Customers
14.3. Systemic Lupus Erythematosus Treatment Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. GlaxoSmithKline
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. F. Hoffmann-La Roche
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Pfizer
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. AstraZeneca
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Merck
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Bristol-Myers Squibb
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Anthera Pharmaceuticals
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. ImmuPharma
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Aurinia Pharmaceuticals
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Systemic Lupus Erythematosus Treatmen
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
